Home / Congress Presentations / C3G and Primary IC-MPGN / Southwest Nephrology Conference (SWNC) 2025
Landing
Southwest Nephrology Conference (SWNC) 2025
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or posttransplant recurrent C3G or primary (idiopathic) IC-MPGN
Pegcetacoplan for adolescents with C3G or IC-MPGN in phase 3 VALIANT
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.